NCT04068610 2026-03-02
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
MedImmune LLC
Phase 1/2 Active not recruiting
MedImmune LLC
Intima Bioscience, Inc.
A2 Biotherapeutics Inc.
Arvinas Inc.